1. Busse R. Disease management programs in Germany’s statutory health insurance system. Health Aff. 2004;23(3):56–67.
2. German Federal (Social) Insurance Authority (2014): Zulassung der strukturierten Behandlungsprogramme (Disease Management Programme – DMP) durch das Bundesversicherungsamt (BVA), [Authorization of Disease Management Programs by the German Federal (Social) Insurance Authority] http://www.bundesversicherungsamt.de/weiteres/disease-management-programme/zulassung-disease-management-programme-dmp.html . Updated December 2014. Accessed 4 Jan 2015.
3. Bundesgesetzblatt Jahrgang 2009 Teil I Nr. 35, Zwanzigste Verordnung zur Änderung der Risikostruktur-Ausgleichsverordnung, [Twentieth regulation on alteration of the risk structure compensation ordinance]; Bonn, (20. RSA-ÄndV) 23. Juni 2009: 1542–69.
4. Schäfer I, Küver C, Gedrose B, von Leitner EC, Treszl A, Wegscheider K, et al. Selection effects may account for better outcomes of the German Disease Management Program for type 2 diabetes. BMC Health Serv Res. 2010;10:351. doi: 10.1186/1472-6963-10-351 .
5. Drabik A, Sawicki PT, Muller D, Passon A, Stock S. The methods within the evaluation of disease management programmes in control-group designs using the example of diabetes mellitus - a systematic literature review. Gesundheitswesen. 2012;74:496–501. doi: 10.1055/s-0031-1301273 .